B of A Securities Initiates Coverage On Turnstone Biologics with Buy Rating, Announces Price Target of $18
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Geoff Meacham has initiated coverage on Turnstone Biologics (NASDAQ:TSBX) with a Buy rating and a price target of $18.
August 15, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Turnstone Biologics has been initiated with a Buy rating by B of A Securities, with a price target of $18.
The initiation of coverage by B of A Securities with a Buy rating and a price target of $18 indicates a positive outlook for Turnstone Biologics. This could potentially attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100